{
    "clinical_study": {
        "@rank": "139439", 
        "arm_group": [
            {
                "arm_group_label": "Oral Sildenafil", 
                "arm_group_type": "Active Comparator", 
                "description": "In group A, newborns received oral Sildenafil solution through feeding tube which was prepared by crushing a 50 mg tablet of sildenafil in distilled water to make a concentration of 5 mg/ml. The protocol for dosing was (1) first dose of 1 mg/kg/dose within 30 minutes admission or within 12 hours of delivery (whichever earlier), (2) Dosing every six hours for a maximum of 8 doses."
            }, 
            {
                "arm_group_label": "Distilled water", 
                "arm_group_type": "Placebo Comparator", 
                "description": "In group B, newborns received placebo. The protocol for dosing was (1) first dose of 1 mg/kg/dose within 30 minutes admission or within 12 hours of delivery (whichever earlier), (2) Dosing every six hours for a maximum of 8 doses."
            }
        ], 
        "brief_summary": {
            "textblock": "The purpose of this study is to to study the role of oral Sildenafil in Persistent Pulmonary\n      Hypertension of Newborn (PPHN) secondary to Meconium Aspiration Syndrome (MAS) in newborns\n      and to study risk factors of MAS developing into PPHN."
        }, 
        "brief_title": "Oral Sildenafil in Persistent Pulmonary Hypertension Secondary to Meconium Aspiration Syndrome in Newborns", 
        "completion_date": {
            "#text": "September 2012", 
            "@type": "Actual"
        }, 
        "condition": [
            "Meconium Aspiration Syndrome", 
            "Persistent Pulmonary Hypertension of Newborn"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Hypertension", 
                "Hypertension, Pulmonary", 
                "Meconium Aspiration Syndrome", 
                "Persistent Fetal Circulation Syndrome"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Newborns were diagnosed with MAS if any of the two of the following three criteria\n             were present. (1) Meconium staining of liquor or staining of umbilical cord or skin\n             or nails. (2) Respiratory distress, within one hour of birth. (3) Radiological\n             evidence of aspiration pneumonitis (atelectasis and/or hyperinflation). Newborns with\n             MAS diagnosed with clinical PPHN  were enrolled in the study for drug trial. PPHN was\n             determined either clinically by loud P2(second component of second heart sound), 10%\n             or greater pre-/post ductal difference in arterial oxygenation (obtained by acid base\n             gas analysis) or upper limb- lower limb SpO2 difference (obtained by pulse oximetry).\n\n        Exclusion Criteria:\n\n          -  (a) babies with congenital heart disease (b) congenital anomalies particularly those\n             which were incompatible to life or which was the cause for respiratory distress e.g.\n             diaphragmatic hernia (c) Respiratory morbidities such as hyaline membrane disease,\n             congenital pneumonia (d) Babies with PPHN secondary to MAS admitted after 12 hours of\n             delivery (e) Non availability of consent of guardian for interventional procedures"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "12 Hours", 
            "minimum_age": "N/A"
        }, 
        "enrollment": {
            "#text": "96", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "December 18, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01757782", 
            "org_study_id": "Sildenafil"
        }, 
        "intervention": [
            {
                "arm_group_label": "Oral Sildenafil", 
                "description": "Patients were randomized into two groups. Placebo was prepared with distilled water. In group A, newborns received oral Sildenafil solution through feeding tube which was prepared by crushing a 50 mg tablet of sildenafil in distilled water to make a concentration of 5 mg/ml. In group B, newborns received placebo. The protocol for dosing was (1) first dose of 1 mg/kg/dose within 30 minutes admission or within 12 hours of delivery (whichever earlier), (2) Dosing every six hours for a maximum of 8 doses, (3) Dose was doubled if the oxygenation index (OI) or SpO2 did not improve (If OI continued to be <10% of previous value and SpO2 was not increasing >5 of previous value) and blood pressure remained stable", 
                "intervention_name": "Oral Sildenafil", 
                "intervention_type": "Drug", 
                "other_name": [
                    "Viagra", 
                    "Integra"
                ]
            }, 
            {
                "arm_group_label": "Distilled water", 
                "intervention_name": "Placebo (distilled water)", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": "Sildenafil"
        }, 
        "is_fda_regulated": "No", 
        "lastchanged_date": "December 21, 2012", 
        "number_of_arms": "2", 
        "official_title": "Oral Sildenafil in Persistent Pulmonary Hypertension Secondary to Meconium Aspiration Syndrome in Newborns: A Randomized Placebo Controlled Trial", 
        "other_outcome": {
            "description": "During time of hospital stay(upto 4 weeks).", 
            "measure": "Mortality of patients enrolled in study", 
            "safety_issue": "Yes", 
            "time_frame": "Upto 4 weeks"
        }, 
        "overall_official": {
            "affiliation": "Professor of Pediatrics, Dept of Pediatrics, Govt Medical College, Bhavnagar, Gujarat, India", 
            "last_name": "Jayendra R Gohil, MD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "India: Institutional Review Board", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 4", 
        "primary_completion_date": {
            "#text": "August 2012", 
            "@type": "Actual"
        }, 
        "primary_outcome": {
            "description": "Preductal and postductal oxygen saturation (SpO2) 2 hours after dose of oral sildenafil (24 hours and 48 hours)", 
            "measure": "Improvement in oxygen saturation (SpO2)", 
            "safety_issue": "No", 
            "time_frame": "26 hours, 50 hours"
        }, 
        "reference": {
            "PMID": "19866403", 
            "citation": "Vargas-Origel A, G\u00f3mez-Rodr\u00edguez G, Aldana-Valenzuela C, Vela-Huerta MM, Alarc\u00f3n-Santos SB, Amador-Licona N. The use of sildenafil in persistent pulmonary hypertension of the newborn. Am J Perinatol. 2010 Mar;27(3):225-30. doi: 10.1055/s-0029-1239496. Epub 2009 Oct 28."
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01757782"
        }, 
        "responsible_party": {
            "investigator_affiliation": "Sir Takhtasinhji General Hospital", 
            "investigator_full_name": "Jayendra R. Gohil", 
            "investigator_title": "Professor in Pediatrics", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "secondary_outcome": {
            "description": "Oxygenation index of neonates kept on ventilator 2 hours after dose of oral sildenafil (24 hours and 48 hours) [Oxygenation index (OI) = Mean airway pressure (cm H2O) \u00d7 FiO2 \u00d7 100/ PaO2 [fraction of inspired oxygen- FiO2] [Arterial partial pressure of oxygen- PaO2]", 
            "measure": "Oxygenation index", 
            "safety_issue": "No", 
            "time_frame": "26 hours, 50 hours"
        }, 
        "source": "Sir Takhtasinhji General Hospital", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Sir Takhtasinhji General Hospital", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "December 2011", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "December 2012"
    }
}